Loading...
XWAR
PTG
Market cap41mUSD
Jul 29, Last price  
32.00PLN
1D
2.50%
1Q
-4.09%
IPO
-47.44%
Name

Poltreg SA

Chart & Performance

D1W1MN
P/E
—
P/S
106.67
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.96%
Rev. gr., 5y
%
Revenues
1m
+40.04%
0500,000700,0001,099,000999,0001,399,000
Net income
-14m
L
-1,350,000-1,165,000-982,000-3,779,0001,298,000-13,551,000
CFO
-13m
L+54.43%
-1,043,000-1,190,000-2,788,000-3,837,000-8,602,000-13,284,000

Profile

Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases using T-regulatory cells. It engages in the research and development of therapies for the treatment of type 1 diabetes in children and in multiple sclerosis. The company is based in Gdansk, Poland.
URL
https://poltreg.tech/
IPO date
Nov 23, 2021
Employees
17
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
1,399
40.04%
999
-9.10%
Cost of revenue
7,163
4,627
Unusual Expense (Income)
NOPBT
(5,764)
(3,628)
NOPBT Margin
Operating Taxes
(3,265)
Tax Rate
NOPAT
(5,764)
(363)
Net income
(13,551)
-1,143.99%
1,298
-134.35%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
393
36
Long-term debt
15,995
15,753
Deferred revenue
12,498
Other long-term liabilities
798
629
Net debt
(49,563)
(74,311)
Cash flow
Cash from operating activities
(13,284)
(8,602)
CAPEX
(31,572)
(7,583)
Cash from investing activities
(31,572)
(5,049)
Cash from financing activities
20,771
(254)
FCF
(36,890)
(21,085)
Balance
Cash
65,951
90,036
Long term investments
64
Excess cash
65,881
90,050
Stockholders' equity
(25,242)
(11,691)
Invested Capital
134,249
121,261
ROIC
ROCE
EV
Common stock shares outstanding
4,663
4,663
Price
49.80
8.26%
46.00
-33.14%
Market cap
232,217
8.26%
214,498
-8.71%
EV
182,654
140,187
EBITDA
(4,713)
(2,805)
EV/EBITDA
Interest
356
284
Interest/NOPBT